Clinical observation and mechanism study on the treatment of post-stroke depression patients with acupuncture combined with pricking-cupping therapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084634

Enrollment

Unknown

Registered

2024-05-22

Start date

2024-05-31

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post stroke depression

Interventions

acupuncture combined with flocculent needling and cupping group:acupuncture combined with flocculent needling and cupping

common acupuncture group:common acupuncture

acupuncture combined with flocculent needling and cupping group:None

common acupuncture group:None

Healthy group:None

Eligibility

Sex/Gender

All

Age

30 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria of traditional Chinese and Western medicine for stroke and depression; (2) The total score of the 24 Hamilton Depression Rating Scale (HAMD-24) is 8-35, indicating mild or moderate depression; (3) Age: 30-85 years old; (4) Gender: unlimited; (5) Not receiving other antidepressant treatments; (6) The patient and their family members agree to participate in the trial, have no difficulty communicating, can cooperate with treatment and examination, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Individuals with consciousness disorders; (2) Individuals with severe intellectual disabilities, aphasia, deafness, and cognitive impairment who are unable to complete efficacy evaluations; (3) Individuals with severe primary diseases such as heart, liver, kidney, lung, digestive system, endocrine system, hematopoietic system, or other serious physical diseases; (4) Coagulation dysfunction patients; (5) Previous history of mental illness and/or family history; (6) Individuals who are addicted to alcohol or psychotropic drugs; (7) Those who feel dizzy with needles, and blood, or do not cooperate with treatment; (8) Those who are unable to sign the informed consent form.

Design outcomes

Primary

Measure	Time frame
HAMD-24;	—

Secondary

Measure	Time frame
SDS;TCM Depression Syndrome Scale Score;NIHSS;Urinary metabolomics;MADRS;NE;ACTH;25 hydroxyvitamin D;thyroid function ;cortisol;Interleukin;	—

Countries

China

Contacts

Public ContactWa Cai; Weidong Shen

Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine

408346323@qq.com+86 136 7166 8310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 29, 2026